comparemela.com

Latest Breaking News On - Mantle cell lymphoma - Page 4 : comparemela.com

Dr Goy on the Rationale for Launching the ZUMA-18 Trial in Relapsed/Refractory MCL

Andre Goy, MD, discusses the evaluation of brexu-cel in the ZUMA-2 and expanded access ZUMA-18 trials in relapsed/refractory mantle cell lymphoma.

United statesAndre goyHackensack meridian health oncology care transformation servicesJohn theurer cancer centerLymphoma divisionHackensack university medical centerJohn theurer cancer centerHackensack university medical centerOnclive tvMantle cell lymphoma

Current Treatment Options in Third-line MCL

Experts on mantle cell lymphoma discuss third-line treatment options available for patients.

Recent updatesFollicular lymphomaMantle cell lymphomaTreatment optionsThird lineThird line mclCart cellsZuma 2Brexu celZuma 2 trialHigh risk patientsOverall survivalLiso celCart cell therapy

Sequencing Therapies in the Third-Line and Beyond Setting for MCL

A panel of experts discuss how to sequence BTK inhibitors and CAR T-cell therapies in patients with MCL.

Recent updatesFollicular lymphomaMantle cell lymphomaBeyond settingSequencing therapyBrexu celBtk inhibitorCart cell therapyLiso cel

Current Treatment Options in Second-line MCL

Experts on mantle cell lymphoma discuss second-line treatment options available for patients.

Recent updatesFollicular lymphomaMantle cell lymphomaTreatment optionsSecond lineCart cell therapyStable diseaseReal world data

Pirtobrutinib Continues to Show Safety, Activity in Covalent BTK Inhibitor–Pretreated R/R MCL

Jonathon B. Cohen, MD, MS, expands on updated data from the BRUIN trial of pirtobrutinib in patients with relapsed BTK-exposed mantle cell lymphoma.

United statesEmory universityJonathonb cohenOncology at emory university school of medicineLymphoma programDepartment of hematologySafety monitoring committeeWinship cancer instituteMedical oncologyEmory university schoolMantle cell lymphoma

vimarsana © 2020. All Rights Reserved.